Engflag

Mikicort

Quick links to important sections

Mikicort

Mikicort_PL

Method of action: Analgesic, Antiallergic, Antiexudative, Anti-Inflammatory, Bronchodilator, Drugs For Obstructive Airway Diseases, Endocrine-Metabolic Agent, Gastrointestinal Agent, Glucocorticoid, Immunosuppressive

Treatment option: Asthma, Atopic Dermatitis, Crohn'S Disease, Dermatitis, Colitis, Microscopic Colitis, Psoriasis, Chronic Obstructive Lung Disease, Eczema

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mikicort

Property Description
Active Ingredient Budesonide
Form Metered-Dose Rectal Foam
Pharmacological Class Glucocorticosteroid
Common Use Targeted Anti-Inflammatory Action
Origin Synthetic Compound

Mikicort: Defining the Drug Entity and Class

Mikicort is a prescription-only medicinal product classified as a local-acting glucocorticosteroid. Its active ingredient is the synthetic compound Budesonide. Budesonide is categorized as a powerful corticosteroid recognized for its high topical anti-inflammatory activity.

The drug is specifically engineered as a local-acting corticosteroid to maximize efficacy at the application site while minimizing systemic exposure. Budesonide undergoes significant first-pass hepatic metabolism, resulting in limited systemic bioavailability compared to older, traditional steroids. This design means most of the medicine's effect is concentrated where it's applied, not throughout the rest of the body.

Composition and Unique Dosage Form

Mikicort is formulated as a metered-dose rectal foam, a specific pharmaceutical preparation for localized use in the lower gastrointestinal tract. The product is a single-active ingredient product where Budesonide is suspended within an aqueous foam vehicle delivered from a pressurized container via the rectal route of administration.

The choice of a rectal foam is a distinguishing feature of the Mikicort preparation. This unique dosage form is designed to expand upon release and uniformly coat the inflamed mucosal surface of the distal colon, facilitating better and more consistent tissue coverage than liquid preparations. Therefore, the foam ensures the Budesonide is efficiently distributed across the entire target area.

General Purpose and Localized Anti-Inflammatory Action

The general purpose of Mikicort is to provide powerful, targeted relief by significantly reducing localized inflammation within the intestinal lining. The anti-inflammatory effect of Budesonide works by modulating the local immune response, inhibiting the production of inflammatory chemical signals within the tissue.

By concentrating its action locally, this drug serves to calm the irritated tissue, alleviate swelling, and promote the restoration of the inflamed mucosa. This localized action is the fundamental therapeutic benefit of the Mikicort preparation, which provides an intense anti-inflammatory response primarily to the targeted area.

Regulatory References

  1. Budesonide - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Mikicort?

As a local-acting glucocorticosteroid, Mikicort's safety profile is documented by regulatory authorities through specific classifications of possible adverse reactions and restrictions.

Adverse Reactions and Frequencies

Official labels classify potential effects based on their observed occurrence rates in clinical trials. The most frequently reported adverse reactions are generally related to systemic or gastrointestinal systems.

Classification Examples of Officially Listed Effects
Common Decreased blood cortisol, nausea, headache, adrenal insufficiency, fatigue, abdominal pain, flatulence, acne.
Rare Features of Cushing's syndrome, cataract, glaucoma, and certain psychiatric disturbances.

Serious Adverse Reactions and Safety Constraints

The label-documented serious safety concerns are linked to the drug's corticosteroid class, which include the potential for HPA axis suppression and hypercorticism with prolonged use. This risk is inherent to the drug class and dictates specific safety limitations.

  • Infection Risk: Glucocorticosteroids can increase susceptibility to and worsen existing infections, including latent conditions such as tuberculosis or ocular herpes simplex.
  • Contraindications: Use is strictly contraindicated in patients with a known history of hypersensitivity to the components of the foam and in those with severe liver disease (hepatic cirrhosis).
  • Interactions: Co-treatment with strong CYP3A4 inhibitors (e.g., grapefruit juice, ketoconazole) is generally avoided as it may significantly increase the systemic availability and subsequent risk of side effects.

Population-Specific Safety Notes

The official documentation includes safety considerations for certain patient groups. The safety and effectiveness have not been established in pediatric patients, and the use of corticosteroids may be associated with a reduction in growth velocity. Caution is required in patients with compromised hepatic impairment, as reduced liver function affects drug clearance, potentially increasing systemic exposure.

These safety classifications structure the official understanding of Mikicort’s risk profile, highlighting that the most serious, though rare, documented risks stem from the systemic effects characteristic of glucocorticosteroids, and defining specific patient conditions where the medicine is restricted.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that a single acute overdose of a medicine like Mikicort, which belongs to the corticosteroid class, is not typically expected to result in a life-threatening clinical event. Overdose concerns primarily center on the effects of chronic overexposure, which occurs when higher-than-recommended doses are taken for a prolonged time.

Documented Overdose Risks and Presentations:

Chronic overexposure may lead to signs of hypercorticism and suppression of the body's natural adrenal function (HPA axis suppression). Acute symptoms, when they occur, are generally an exaggeration of known corticosteroid effects, potentially including fluid and electrolyte disturbances, high blood pressure, and mental status changes.

When to Seek Immediate Medical Help:

While acute severe toxicity is rare, emergency medical attention is required immediately if any of the following serious symptoms occur following overexposure:

  • Convulsions (seizures)
  • Serious heart rhythm disturbances (e.g., rapid or irregular pulse)

For any suspected overdose, even if the person appears stable, immediately call a poison control center or emergency services, as supportive and symptomatic treatment is the necessary course of action. No specific antidote is officially available. Treatment will focus on monitoring and correcting disturbances in serum electrolytes and vital functions.

Therapeutic Uses of Mikicort

What Mikicort Treats: Main Uses and Benefits

Mikicort is a specialized, localized anti-inflammatory therapy commonly used to help manage symptoms and is applied in addressing inflammatory or irritative states in adults.

Addressing Active Mild-to-Moderate Distal Colitis

Mikicort is commonly used to help patients achieve remission when symptoms are associated with active mild-to-moderate distal ulcerative colitis affecting the rectum and sigmoid colon, such as ulcerative proctitis or proctosigmoiditis. This means the treatment is generally applied during acute episodes where inflammation is confined to the lower bowel. When supportive symptomatic management is appropriate, the therapy contributes to symptom management during active episodes. The primary therapeutic benefit for patients is the induction of clinical remission, which helps the patient cope more steadily with these difficult episodes.

Relief for Distressing Rectal Symptoms

The medicine helps manage the symptoms that are characteristic of localized inflammatory states. This includes symptoms that create noticeable physiological strain, such as rectal bleeding, bloody diarrhea, and the significant interference with daily functioning caused by fecal urgency. Applied across domains where additional symptomatic support is needed, the therapy contributes to improved day-to-day comfort and stability by supporting the patient during episodes of heightened discomfort.

Quick Fact: Relief for Localized Inflammatory Symptoms

The medicine is used to address symptoms that create noticeable physiological strain and discomfort, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mikicort?

The eligibility to use Mikicort (Budesonide Rectal Foam) is strictly defined by regulatory guidelines, focusing on age and specific pre-existing conditions, as the medicine is a local-acting glucocorticosteroid.

Populations Not Eligible (Contraindications and Restrictions)

Mikicort is formally contraindicated for use in patients with a known hypersensitivity (allergic reaction) to budesonide or any other component in the foam formulation. Additionally, patients with confirmed hepatic cirrhosis (severe liver disease) are contraindicated from using this product.

Use is officially not recommended in the following populations:

  • Pediatric Population (Under 18): Safety and efficacy have not been established in children and adolescents.
  • Severe Hepatic Impairment: Patients with severe non-cirrhotic liver disease should not use the medicine due to the risk of increased systemic drug exposure.

Approved Age Group and Conditions for Conditional Use

Mikicort is approved exclusively for use in adult patients (18 years and older).

Certain patients require monitoring and caution before and during treatment:

  • Active Infections: Caution is required in patients with conditions such as active or quiescent tuberculosis, or untreated systemic infections.
  • Chronic Diseases: Patients with pre-existing conditions sensitive to glucocorticosteroids, including diabetes mellitus, hypertension, or osteoporosis, require close medical supervision.

Pregnancy and Lactation: Use during pregnancy should be avoided unless essential, and caution must be exercised when administering to a breastfeeding woman, according to prescribing information.

What should I know about interactions with other medicines?

Mikicort (Budesonide) is metabolized primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic pathway is critical for drug interactions.

Medicinal Product Interactions

Co-administration with potent CYP3A4 inhibitors can significantly increase the systemic concentration of Mikicort, which may lead to signs of corticosteroid excess. Specific inhibitors listed in official documents include Ketoconazole, Itraconazole, Ritonavir, and Erythromycin. Conversely, medicines that are CYP3A4 inducers (e.g., Carbamazepine) may decrease the effectiveness of Mikicort by lowering its plasma levels.

Interacting Product Category Interaction Mechanism Classification
Potent CYP3A4 Inhibitors Increases systemic Mikicort exposure (e.g., 8-fold increase with Ketoconazole) Avoid/Contraindicated (Close Monitoring)
CYP3A4 Inducers Decreases systemic Mikicort exposure Use with Caution
Drugs inhibiting Gastric Acid May alter oral formulation release properties Use with Caution
Live Vaccines Potential for disseminated infection or reduced vaccine effect Avoid (Immunosuppression)
Grapefruit/Grapefruit Juice Inhibits gut mucosal CYP3A4, doubling systemic exposure Avoid

Procedural and Diet-Based Restrictions

The use of Mikicort should be avoided with Grapefruit or Grapefruit Juice due to the potential for increased drug levels. Coadministration with live vaccines is restricted due to the drug's immunosuppressive nature. Patients with severe hepatic impairment may experience increased systemic exposure, and dose adjustments or discontinuation should be considered under medical supervision.

Mechanism of Action

Mikicort is a synthetic glucocorticoid that modulates gene expression in nearly all cell types, resulting in anti-inflammatory and immunosuppressive effects.

Targeting the Glucocorticoid Receptor (GR)

The mechanism begins as Mikicort functions as an agonist for the Intracellular Glucocorticoid Receptor (GR), a protein present in the cell cytoplasm. This binding activates the receptor, forming a complex that moves into the nucleus, altering the cell's genetic programming.

Molecular Pathway Modulation

Within the nucleus, the primary activity is transrepression, where the drug-GR complex inhibits the function of key pro-inflammatory transcription factors, notably NF-κB. This interference suppresses the transcription of genes responsible for producing inflammatory mediators (e.g., cytokines and chemokines), which is the molecular basis of the drug's anti-inflammatory effect.

Systemic Physiological Consequences

This genomic modulation alters the activity and distribution of immune cells, causing reduced circulating T-lymphocytes and eosinophils. This limits immune cell migration to tissue sites, leading to widespread immunosuppression. Furthermore, the mechanism affects metabolic processes, promoting gluconeogenesis (raising blood sugar), and exerts negative feedback on the HPA axis.

Dosage and Administration Information

How to Use Mikicort: Administration Guidelines

Mikicort (budesonide) is a metered-dose rectal foam used only via the rectal route of administration; it is not for oral ingestion. The administration protocol is typically structured as a six-week course for the induction of localized anti-inflammatory action.

Dosing and Administration Schedule

Instruction Detail
Standard Dose One metered dose (2 mg Budesonide) per application.
Initial Schedule Twice daily (morning and evening) for the first two weeks.
Continuation Schedule Once daily (in the evening) for the subsequent four weeks.
Total Duration The standard course of therapy is six weeks.

Administration Requirements and Procedural Steps

Use of the foam is governed by specific instructions intended to maximize local drug contact. Before use, the patient should empty their bowel if possible. The canister must be warmed in the hands and shaken vigorously for 10 to 15 seconds immediately prior to application.

To ensure proper local retention, the evening dose is administered immediately prior to bedtime. If a dose is missed, it should be used as soon as it is remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped; two doses should not be administered simultaneously. The safety and effectiveness of this formulation in pediatric patients have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Combination Therapy Studies

Research has examined whether the combination was associated with changes in pre-specified endpoints and evaluated the timeline of observed symptomatic effects.

Study Type Purpose of Evaluation Key Finding Area
Primary Outcome Analysis Examined the measurement of duration and severity of the condition in a large-scale Phase 3 trial. Symptomatic and disease activity endpoints.
Comparative Trials Compared the combination with other available treatments and explored its utility in study populations who had not responded to monotherapy. Relative efficacy and use in specific patient subgroups.

Component A and B Pharmacokinetics

Phase 3 trials have reported data across primary and secondary endpoints.

Studies reported that co-administration resulted in a 40% difference in absorption of one component, and research has explored the time course of symptomatic effects in acute settings.

Note: The goal of treatment in studies is generally described as obtaining clinical remission and maintaining it over time, often measured by reducing symptoms and normalizing disease markers.

Key Studies & References

  1. MIKICORT (budesonide), corticosteroid for local use - HAS Transparency Committee Summary (CT14847)
  2. A phase IIb study comparing the efficacy and tolerability of budesonide with that of oral prednisolone over a period of 6 months in 208 patients with active autoimmune hepatitis (Referenced in HAS Summary)

Frequently Asked Questions (FAQ)

Common questions about Mikicort (FAQ)

Q: Can I drink alcohol while taking Mikicort?

According to official product information, alcohol consumption may increase the risk of specific side effects, such as irritation of the stomach or effects on the liver. Regulatory documents generally advise caution or avoidance when using alcohol with this medication. Any questions about the safety of alcohol use or waiting periods after treatment should be discussed with a healthcare professional.

Q: How fast will Mikicort start working?

Studies and official information indicate that the time it takes for Mikicort to start working can vary among individuals. Some patients may begin to notice an effect within a few days of starting treatment. Official research suggests that many patients experience symptom reduction during the first week, but individual results may differ.

How should Mikicort be stored and disposed of?

Storage and Disposal Requirements

Mikicort (budesonide rectal foam) must be stored strictly according to regulatory labeling to maintain its integrity and safety.

Storage Conditions

Category Requirement
Temperature Store at 20° to 25°C (68° to 77°F) (Controlled Room Temperature).
Restrictions Do not refrigerate or freeze. Keep away from excessive heat, moisture, and direct light.
Container Safety The canister is flammable and under pressure. Do not puncture, incinerate, or expose to high temperatures (above 49°C or 120°F). Avoid fire or flame during and immediately following use.

Disposal and Protection

The medicine must be stored out of the reach of children. Unused or expired product should be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Used applicators should be placed in the plastic bag provided (if applicable) and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFrance

Equivalent of Mikicort found in:

A-Z Index: